{"id":"l-folinic","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Allergic reactions (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"L-folinic acid serves as a source of one-carbon units that potentiate the cytotoxic effects of 5-fluorouracil (5-FU) and related antimetabolites. By providing the necessary cofactor, it increases the duration and stability of the inhibitory complex at thymidylate synthase, thereby enhancing DNA synthesis inhibition and improving chemotherapy efficacy. It is commonly used as an adjunct to fluoropyrimidine-based regimens in colorectal and other cancers.","oneSentence":"L-folinic acid (leucovorin) is a reduced form of folic acid that enhances the activity of fluorouracil-based chemotherapy by stabilizing the ternary complex between fluorodeoxymonophosphate, thymidylate synthase, and the cofactor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:05.456Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (adjuvant and metastatic, in combination with 5-fluorouracil)"},{"name":"Gastric cancer"},{"name":"Breast cancer (in combination with fluoropyrimidines)"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT07437287","phase":"PHASE2, PHASE3","title":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-07","conditions":"Biliary Tract Cancer (BTC)","enrollment":160},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02981628","phase":"PHASE2","title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-06-19","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT07359456","phase":"PHASE2","title":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-03","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT05802056","phase":"PHASE1","title":"Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-29","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":15},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT06846346","phase":"PHASE2","title":"Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-20","conditions":"Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma","enrollment":88},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":488},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT06783491","phase":"PHASE3","title":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-12-31","conditions":"Locally Advanced Colorectal Cancer","enrollment":1083},{"nctId":"NCT02967289","phase":"PHASE3","title":"IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-27","conditions":"Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)","enrollment":792},{"nctId":"NCT04821284","phase":"PHASE1, PHASE2","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Flemming Forsberg","startDate":"2021-12-06","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":120},{"nctId":"NCT06790706","phase":"PHASE2","title":"IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-10-01","conditions":"Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma","enrollment":154},{"nctId":"NCT05052099","phase":"PHASE1, PHASE2","title":"Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2021-10-22","conditions":"Biliary Tract Cancer","enrollment":20},{"nctId":"NCT05192889","phase":"PHASE1, PHASE2","title":"Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-08-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT07118800","phase":"PHASE3","title":"Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2025-12-15","conditions":"Locally Advanced Rectal Adenocarcinoma","enrollment":160},{"nctId":"NCT03493048","phase":"PHASE2","title":"Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-04-15","conditions":"Colorectal Cancer, Liver Metastases","enrollment":146},{"nctId":"NCT00878254","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2009-03-25","conditions":"Mantle-Cell Lymphoma","enrollment":25},{"nctId":"NCT03828227","phase":"PHASE3","title":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-06-14","conditions":"Elderly Patients, Metastatic Colorectal Cancer, Quality of Life","enrollment":49},{"nctId":"NCT05712356","phase":"PHASE2","title":"A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisata Therapeutics, Inc.","startDate":"2023-08-24","conditions":"Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma","enrollment":67},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT05312398","phase":"PHASE2","title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-07-15","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":219},{"nctId":"NCT04060030","phase":"PHASE2","title":"Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism","status":"RECRUITING","sponsor":"Southwest Autism Research & Resource Center","startDate":"2020-10-08","conditions":"Autism Spectrum Disorder, Language Disorders","enrollment":80},{"nctId":"NCT04060017","phase":"PHASE2","title":"Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium","status":"RECRUITING","sponsor":"Southwest Autism Research & Resource Center","startDate":"2020-09-22","conditions":"Autism Spectrum Disorder, Language Disorders","enrollment":80},{"nctId":"NCT02839915","phase":"PHASE2","title":"Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Southwest Autism Research & Resource Center","startDate":"2020-08-13","conditions":"Autism Spectrum Disorder","enrollment":56},{"nctId":"NCT02896907","phase":"EARLY_PHASE1","title":"Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2016-10-18","conditions":"Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer","enrollment":8},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895},{"nctId":"NCT01190930","phase":"PHASE3","title":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2010-08-09","conditions":"Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma","enrollment":9350},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT04825288","phase":"PHASE1, PHASE2","title":"XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"XBiotech, Inc.","startDate":"2021-05-27","conditions":"Pancreatic Cancer","enrollment":76},{"nctId":"NCT02828358","phase":"PHASE2","title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-01","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":78},{"nctId":"NCT01878422","phase":"PHASE3","title":"Sequential Treatment Strategy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2007-11","conditions":"Metastatic Colorectal Cancer","enrollment":376},{"nctId":"NCT06475352","phase":"PHASE2","title":"Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-01-20","conditions":"Digestive Cancer, Colorectal Cancer","enrollment":400},{"nctId":"NCT03719924","phase":"PHASE2","title":"Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2019-03-07","conditions":"Squamous Cell Carcinoma","enrollment":106},{"nctId":"NCT05314998","phase":"PHASE3","title":"Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature","status":"NOT_YET_RECRUITING","sponsor":"John Neoptolemos","startDate":"2025-01-15","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":394},{"nctId":"NCT05476796","phase":"PHASE2","title":"Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-06-23","conditions":"Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":118},{"nctId":"NCT02514278","phase":"PHASE3","title":"Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-01-28","conditions":"Rectal Cancer","enrollment":218},{"nctId":"NCT06509126","phase":"PHASE3","title":"Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2024-06-12","conditions":"Colorectal Cancer Stage IV","enrollment":500},{"nctId":"NCT03488225","phase":"PHASE2","title":"Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-28","conditions":"Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":4},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":"Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia","enrollment":218},{"nctId":"NCT03351296","phase":"PHASE2","title":"Two Chemotherapy Regimens Plus or Minus Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-06-26","conditions":"Pancreatic Cancer","enrollment":140},{"nctId":"NCT06391892","phase":"PHASE3","title":"Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","status":"RECRUITING","sponsor":"Elisabethinen Hospital","startDate":"2024-01-11","conditions":"Pancreatic Cancer, Circulating Tumor Cell, Predictive Cancer Model","enrollment":100},{"nctId":"NCT06383078","phase":"PHASE2","title":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-20","conditions":"Efficacy and Safety","enrollment":120},{"nctId":"NCT02539537","phase":"PHASE3","title":"A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2015-10-23","conditions":"Pancreatic Cancer, Carcinoma","enrollment":171},{"nctId":"NCT00098787","phase":"PHASE2","title":"Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-09-08","conditions":"Colorectal Cancer","enrollment":247},{"nctId":"NCT02620865","phase":"PHASE1, PHASE2","title":"BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2015-12","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer","enrollment":2},{"nctId":"NCT01256398","phase":"PHASE2","title":"Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":66},{"nctId":"NCT00467142","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2007-01-23","conditions":"Colorectal Cancer","enrollment":62},{"nctId":"NCT03665441","phase":"PHASE3","title":"Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC","status":"COMPLETED","sponsor":"ERYtech Pharma","startDate":"2018-09-15","conditions":"Pancreatic Adenocarcinoma","enrollment":512},{"nctId":"NCT03487016","phase":"PHASE2","title":"First-line Therapy in Metastatic PDAC","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2019-02-15","conditions":"Metastatic Pancreatic Cancer","enrollment":270},{"nctId":"NCT03524508","phase":"PHASE2","title":"Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"Changhoon Yoo","startDate":"2018-09-04","conditions":"Metastatic Biliary Tract Cancer","enrollment":178},{"nctId":"NCT04756713","phase":"PHASE3","title":"Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-11","conditions":"Gestational Trophoblastic Neoplasia, Molar Pregnancy, Gestational Trophoblastic Tumor, Non-Metastatic","enrollment":150},{"nctId":"NCT03294252","phase":"PHASE1, PHASE2","title":"Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers","status":"TERMINATED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2017-05-24","conditions":"Digestive Cancer","enrollment":34},{"nctId":"NCT01442649","phase":"PHASE2","title":"Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2010-12","conditions":"Colorectal Cancer","enrollment":133},{"nctId":"NCT01526135","phase":"PHASE3","title":"Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-04-16","conditions":"Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)","enrollment":493},{"nctId":"NCT01481272","phase":"PHASE2","title":"Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Polish Lymphoma Research Group","startDate":"2011-11","conditions":"Diffuse Large B Cell Lymphoma","enrollment":77},{"nctId":"NCT00210184","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2004-07-21","conditions":"Gastric Cancer","enrollment":42},{"nctId":"NCT01276379","phase":"PHASE2","title":"Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2011-01","conditions":"Colorectal Cancer","enrollment":221},{"nctId":"NCT00103285","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-04-11","conditions":"Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":5377},{"nctId":"NCT00075725","phase":"PHASE3","title":"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2003-12-29","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":3154},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT01443065","phase":"PHASE2","title":"MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2011-01","conditions":"Malignant Neoplasm of Esophagus, Malignant Neoplasm of Stomach","enrollment":162},{"nctId":"NCT01858649","phase":"PHASE2","title":"Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2013-05","conditions":"Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT04167007","phase":"PHASE3","title":"FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-07-20","conditions":"Pancreatic Adenocarcinoma","enrollment":400},{"nctId":"NCT03300609","phase":"PHASE3","title":"5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2018-02-27","conditions":"Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7","enrollment":4},{"nctId":"NCT01836432","phase":"PHASE3","title":"Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2013-05","conditions":"Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm","enrollment":302},{"nctId":"NCT02405585","phase":"PHASE2","title":"Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2015-04","conditions":"Pancreatic Cancer, Pancreatic Carcinoma Non-resectable","enrollment":10},{"nctId":"NCT02779283","phase":"PHASE1","title":"Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2016-01-13","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT00720109","phase":"PHASE2, PHASE3","title":"Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":63},{"nctId":"NCT01926236","phase":"PHASE3","title":"Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2014-02","conditions":"Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma","enrollment":162},{"nctId":"NCT00941655","phase":"PHASE3","title":"Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-22","conditions":"Gastric Cancer","enrollment":15},{"nctId":"NCT01802645","phase":"PHASE2","title":"Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2013-03","conditions":"Colorectal Cancer","enrollment":91},{"nctId":"NCT00004228","phase":"PHASE3","title":"Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-06","conditions":"Lymphoma","enrollment":393},{"nctId":"NCT03121807","phase":"NA","title":"Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2014-09-01","conditions":"Metastatic Gastric Cancer","enrollment":25},{"nctId":"NCT01479465","phase":"PHASE2","title":"Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2011-12","conditions":"Colorectal Cancer","enrollment":266},{"nctId":"NCT02970916","phase":"PHASE2","title":"Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2016-11","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT00068692","phase":"PHASE3","title":"Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-10-15","conditions":"Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma","enrollment":225},{"nctId":"NCT01895257","phase":"PHASE3","title":"Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer","status":"UNKNOWN","sponsor":"Universiteit Antwerpen","startDate":"2013-08","conditions":"Colorectal Cancer","enrollment":162},{"nctId":"NCT00381862","phase":"PHASE2","title":"Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-06","conditions":"Colorectal Cancer, Nausea and Vomiting","enrollment":54},{"nctId":"NCT01134666","phase":"","title":"An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-11-30","conditions":"Colorectal Neoplasms","enrollment":165},{"nctId":"NCT01646554","phase":"PHASE2, PHASE3","title":"Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2012-12","conditions":"Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer","enrollment":""},{"nctId":"NCT00096135","phase":"NA","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-11","conditions":"Leukemia","enrollment":168},{"nctId":"NCT01289821","phase":"PHASE2","title":"First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-02","conditions":"Colorectal Neoplasms","enrollment":54},{"nctId":"NCT00154102","phase":"PHASE3","title":"Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-05","conditions":"Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer","enrollment":1221},{"nctId":"NCT03034850","phase":"","title":"Thrombin Generation and Platelet Activation in CRS/HIPEC","status":"COMPLETED","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2015-04","conditions":"Mesothelioma; Peritoneum, Pseudomyxoma Peritonei, Peritoneal Carcinomatosis","enrollment":27},{"nctId":"NCT01572324","phase":"PHASE2","title":"Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas","status":"COMPLETED","sponsor":"Peking University","startDate":"2012-03","conditions":"Biliary Tract Cancer","enrollment":37},{"nctId":"NCT01508000","phase":"PHASE2","title":"Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2013-06","conditions":"Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer","enrollment":44},{"nctId":"NCT01522612","phase":"PHASE2","title":"Colorectal Cancer (CRC) Cetuximab Elderly Frail","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2013-04","conditions":"Colorectal Cancer Metastatic","enrollment":5},{"nctId":"NCT00572741","phase":"NA","title":"Treating Oxidative Stress and the Metabolic Pathology of Autism","status":"COMPLETED","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2008-06","conditions":"Autistic Disorder","enrollment":39},{"nctId":"NCT01858662","phase":"PHASE2","title":"Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2014-01","conditions":"Metastatic Colorectal Cancer","enrollment":4},{"nctId":"NCT00943137","phase":"PHASE2","title":"The Optimization of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2009-06","conditions":"Cancer (Advanced Stage)","enrollment":55},{"nctId":"NCT01375816","phase":"PHASE2","title":"Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2011-05","conditions":"Colorectal Cancer","enrollment":55},{"nctId":"NCT00778830","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-02","conditions":"Metastatic Colorectal Cancer","enrollment":289}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"NEUTROPENIA"}],"_approvalHistory":[],"publicationCount":51,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"L-folinic","genericName":"L-folinic","companyName":"UNICANCER","companyId":"unicancer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-folinic acid (leucovorin) is a reduced form of folic acid that enhances the activity of fluorouracil-based chemotherapy by stabilizing the ternary complex between fluorodeoxymonophosphate, thymidylate synthase, and the cofactor. Used for Colorectal cancer (adjuvant and metastatic, in combination with 5-fluorouracil), Gastric cancer, Breast cancer (in combination with fluoropyrimidines).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}